Axsome director granted 1,721 restricted stock units
Coleman Mark reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Coleman Mark reported acquisition or exercise transactions in this Form 4 filing.
Axsome Therapeutics director Mark Coleman received a grant of 1,721 restricted stock units. Each RSU represents a contingent right to receive one share of Axsome common stock. The award vests in full on the one-year anniversary of the grant date, after which the underlying common shares become deliverable, increasing his equity-based compensation stake in the company.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 1,721 | $0.00 | $0.00 |
Footnotes (2)
- F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- F2. The RSUs vest in full on the one-year anniversary of the date of grant.
Key Figures
Key Terms
Restricted Stock Units financial
RSU financial
contingent right financial
vest in full financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Axsome Therapeutics (AXSM) director Mark Coleman report on this Form 4?
How many Axsome Therapeutics (AXSM) restricted stock units did Mark Coleman receive?
When do Mark Coleman’s Axsome (AXSM) restricted stock units vest?
How many Axsome (AXSM) restricted stock units does Mark Coleman hold after this grant?
AI-generated analysis. How Rhea-AI works. Not financial advice.